Physician profile
Monette Par
NPI 1881467181
$6,905.07
in general payments reported to CMS, 2019-2025
20 companies · $3,993 in 2025
The $3,993 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $246 · 2024: $2,667 · 2025: $3,993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,905.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,116.15 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $816.78 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $622.21 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $533.25 | 2023-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $516.31 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $506.22 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $496.75 | 2024-2025 | |
| Glaxosmithkline, LLC. | $356.02 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.88 | 2024-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $273.82 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $238.85 | 2024-2025 | Otezla, Repatha, Otezla |
| Aimmune Therapeutics, INC. | $211.26 | 2024-2025 | Zenpep, Vowst |
| Xeris Pharmaceuticals, INC. | $176.90 | 2024 | Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $129.78 | 2023-2025 | Xarelto, Spravato |
| Axsome Therapeutics, INC. | $121.23 | 2025 | Auvelity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $121.11 | 2025 | |
| Kyowa Kirin, INC. | $117.56 | 2025 | |
| Exact Sciences Corporation | $111.15 | 2025 | Cologuard Collection Kit |
| Lundbeck LLC | $110.79 | 2024-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $17.05 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monette Par listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.